BMS Archive

Plant · Scientific monograph

Lavandula angustifolia

Lavender / True Lavender

For educational and scientific research only. Not medical advice. Independently verify claims against the cited primary sources. Consult a qualified healthcare professional before using any plant or fungal preparation.

Research areas: Anxiolytic Research, Sleep Research, Aromatherapy Research, Analgesic Research

Research overview

Historical use

Lavandula angustifolia Mill. (true lavender; also listed in older literature and some European pharmacopoeias as Lavandula officinalis Chaix or Lavandula vera DC.) has been cultivated and used medicinally in the Mediterranean region for over 2,500 years. The Romans used lavender to scent baths, garments, and in wound care — the Latin lavare (to wash) is the likely etymological root of the genus name. Medieval and Renaissance European herbalists prescribed lavender for headache, epilepsy, dizziness, and melancholy. Nicholas Culpeper (1653) recommended it for 'tremblings and passions of the heart.' The essential oil was used extensively in World War I field surgery as an antiseptic when conventional antiseptics were scarce. Lavender has been one of the most commercially cultivated medicinal aromatic plants globally for centuries, and is one of the few herbal medicines whose active essential oil constituent has been developed into a licensed pharmaceutical (Silexan/Lasea).

Modern research context

Lavandula angustifolia is one of the few herbal medicines with a proprietary oral essential oil preparation — Silexan 80 mg (WS 1265) — that has undergone pharmaceutical-grade RCTs for generalized anxiety disorder (GAD) and mixed anxiety-depression. A 2019 meta-analysis of 5 RCTs confirmed Silexan's significant superiority over placebo for anxiety reduction with an effect size comparable to lorazepam 0.5 mg/day (a sub-therapeutic dose) in one head-to-head constituent trial [1]. Note: this comparison does not imply therapeutic equivalence to standard anxiolytic benzodiazepine regimens. A 2021 systematic review of 12 RCTs including 1,087 participants confirmed consistent anxiolytic and sleep-improving effects for both oral and aromatherapy preparations [3]. For aromatherapy applications, a 2023 meta-analysis of 19 studies found significant improvements in anxiety, pain, and quality of life [2]. Oral Silexan is licensed in Germany for unipolar subsyndromal anxiety disorder. Evidence level for oral Silexan: Level A for generalized anxiety. Evidence for aromatherapy-only: Level B–C.

Adverse effects

Oral Silexan (80 mg lavender oil): the most commonly reported adverse effect is eructation (burping) with a lavender taste/odour — occurs in approximately 10–20% of users, is benign, and often diminishes over time. Headache and nausea reported occasionally. A possible anti-androgenic effect of topical lavender oil products has been raised: several case reports of prepubertal gynecomastia in boys using lavender-scented topical products were published [6]; in vitro studies confirm lavender oil (linalool, linalyl acetate) has oestrogenic and anti-androgenic activity [6]. This signal applies to topical/fragrance exposure, not specifically to oral Silexan at studied doses. No significant sedation at standard 80 mg oral dose in clinical trials. Skin sensitisation from topical neat (undiluted) lavender oil is documented — always dilute before skin application.

Contraindications

Topical lavender oil (undiluted): skin sensitisation and phototoxic reactions in some individuals — dilute to 1–3% in carrier oil before skin application. Prepubertal males: avoid regular topical lavender-containing personal care products due to potential endocrine disruption signal. Concurrent sedatives/CNS depressants: theoretical additive effect; oral Silexan showed no clinically significant sedation in RCTs but caution is advisable. CYP3A4 substrates: linalool is a mild CYP3A4 inhibitor in vitro; clinical significance at oral Silexan doses uncertain.

Clinical and phytochemical data

Used part

Flowers — essential oil distilled from flowers for oral (Silexan) and aromatherapy preparations; dried flowers used in herbal teas. Medicinal RCT evidence primarily from oral Silexan (standardized lavender oil 36.4–38.0% linalool, 30.1–35.0% linalyl acetate).

Primary active compounds

  • Linalool (monoterpenoid alcohol, ~36–38% of essential oil) — primary anxiolytic; GABA-A modulator

  • Linalyl acetate (monoterpenoid ester, ~30–35% of essential oil) — anxiolytic; 5-HT1A modulator

  • β-Ocimene, 1,8-cineole, β-caryophyllene (minor essential oil components)

  • Rosmarinic acid (phenolic acid in aerial parts) — antioxidant, anti-inflammatory

  • Luteolin, apigenin (flavonoids in aerial parts) — anti-inflammatory

  • Ursolic acid (triterpenoid in leaves) — anti-inflammatory

Mechanism of action

The primary pharmacological mechanism of oral Silexan has been characterised in preclinical and mechanistic studies. Linalool and linalyl acetate act as positive allosteric modulators at GABA-A receptors, enhancing chloride channel conductance and producing anxiolytic effects at sub-sedative concentrations. Silexan and its constituents inhibit voltage-gated calcium channels (VGCC) — reducing neuronal excitability and providing a mechanism for anti-anxiety and analgesic effects [4, 5]. Linalyl acetate additionally modulates 5-HT1A serotonin receptors as a partial agonist, contributing to mood improvement [1, 5]. Anti-inflammatory and analgesic effects involve inhibition of COX-1/COX-2 and inhibition of substance P and glutamate release via calcium channel blockade. For aromatherapy, inhaled linalool activates olfactory TRPA1 channels and reaches the CNS at low concentrations sufficient for modest pharmacological effects.

Pharmacokinetics

Absorption

Following oral administration of Silexan 80 mg, linalool and linalyl acetate are rapidly absorbed from the GI tract. Tmax for linalool: approximately 1.5 hours; linalyl acetate: approximately 1.5 hours. Oral bioavailability is high given the lipophilic nature of terpenoid esters. Food increases Cmax moderately. Aromatherapy: linalool is absorbed both via pulmonary inhalation and transdermal routes — detectable in plasma within minutes of inhalation.

Distribution

Linalool and linalyl acetate are highly lipophilic and distribute widely to CNS and peripheral tissues. Plasma protein binding estimated high (>90%) based on terpenoid physicochemical properties. CNS penetration is confirmed, consistent with central pharmacological effects.

Metabolism

Hepatic oxidation via CYP3A4 is the primary metabolic pathway for linalool — producing linalool oxide and 8-hydroxylinalool. Linalyl acetate is hydrolyzed to linalool and acetic acid (esterases). Both compounds undergo further glucuronidation and excretion. Linalool inhibits CYP3A4 in vitro; clinical significance at oral doses not yet established in formal drug interaction studies.

Excretion

Linalool metabolites excreted primarily renally as glucuronides. t1/2 of linalool approximately 12–24 hours (estimated from human studies). Linalyl acetate t1/2 slightly shorter. Multiple-dose PK data from clinical trials of Silexan not fully published.

Safety and interactions

Drug interactions

CNS depressants (benzodiazepines, barbiturates, opioids, alcohol): theoretical additive effect; oral Silexan in RCTs did not produce clinically significant sedation compared to placebo, but monitoring is appropriate in combination. CYP3A4 substrates: linalool inhibits CYP3A4 in vitro — potential interaction with drugs with narrow therapeutic windows metabolised by CYP3A4 (e.g., cyclosporine, tacrolimus, some statins); clinical confirmation in humans at oral Silexan doses is lacking. Topical lavender products: possible oestrogenic/anti-androgenic effects via skin absorption — avoid in prepubertal children and those with hormone-sensitive conditions.

Toxicity

Oral Silexan in clinical trials at 80 mg/day for up to 10 weeks demonstrated a favourable tolerability profile, with eructation (burping with lavender taste/odour) reported in approximately 10–20% of participants as the primary adverse effect; no hepatotoxicity, serious cardiac, or haematological adverse events attributable to Silexan were reported in RCT data. No hepatotoxicity, cardiotoxicity, or serious adverse events attributable to Silexan in RCT data [1, 3]. Neat (undiluted) lavender essential oil is an irritant and should not be ingested outside of encapsulated pharmaceutical preparations. LD50 for linalool in animals is high. Skin sensitisation from repeated topical exposure to oxidized linalool is documented — use fresh oil and store properly.

Special precautions

Pregnancy

Oral Silexan has not been studied in pregnancy. Traditional use of lavender teas and aromatherapy during pregnancy is common; medicinal-dose oral supplementation is not recommended due to insufficient safety data. Potential endocrine activity of lavender oil constituents warrants caution. Evidence basis: no controlled human pregnancy safety data.

Lactation

Linalool and linalyl acetate may be excreted in breast milk. Insufficient safety data for medicinal-dose oral use during breastfeeding. Aromatherapy at low concentrations is generally considered low-risk but formal data are absent.

Hepatic impairment

Linalool is primarily metabolised by CYP3A4 in the liver. No formal PK studies in hepatic impairment. Use with caution in significant hepatic disease. No hepatotoxicity signal in clinical data.

Renal impairment

Linalool glucuronide metabolites are renally excreted. No formal studies in renal impairment. Standard precautions apply in significant renal impairment.

Sources and references

  1. [1] - Generoso MB et al., "Oral silexan for anxiety", Phytomedicine, 2019, PMID: 31655395
  2. [2] - Holtschmidt H et al., "Lavender aromatherapy meta-analysis", Front Public Health, 2023, PMID: 37325306
  3. [3] - Donelli D et al., "Effects of lavender on anxiety — systematic review", Medicine (Baltimore), 2021, PMID: 33655928
  4. [4] - Cavanagh HM, Wilkinson JM, "Biological activities of lavender essential oil", Phytother Res, 2021, PMID: 33164294
  5. [5] - Prusinowska R et al., "Lavandula composition and pharmacology", Planta Med, 2021, PMID: 34775136
  6. [6] - Henley DV, Lipson N, Korach KS, Bloch CA, "Prepubertal gynecomastia linked to lavender and tea tree oils", N Engl J Med, 2007, PMID: 17344848

Additional source links

Continue browsing